Syngene International has reported export revenues of $6.6 million for February, marking a notable decline across both year-on-year and month-on-month comparisons. The pharmaceutical services company's latest export figures reflect challenging market conditions during the reported period.

Export Performance Analysis

The company's February export performance showed significant contractions across multiple timeframes. The data reveals both short-term and longer-term pressures on the company's international business operations.

Market Impact

The 22% year-on-year decline indicates sustained pressure on the company's export business compared to the same period in the previous year. Additionally, the 32% month-on-month decrease from January suggests intensifying challenges in the company's international operations during the recent period.

These export figures represent a key performance indicator for Syngene International's international business segment, reflecting the company's ability to serve global pharmaceutical and biotechnology clients. The dual decline across both comparative periods highlights the current operational environment facing the pharmaceutical services sector.

Syngene International Limited has announced comprehensive changes to its senior management team, involving the departure of three key executives and the appointment of two new senior leaders. The changes, disclosed under Regulation 30 of SEBI Listing Regulations on March 6, 2026, will take effect between April 30 and May 1, 2026.

Executive Departures

Three senior management personnel will be leaving the company by mutual consent on April 30, 2026:

All three executives are members of the Executive Committee and hold Senior Management Personnel positions within the organization.

New Leadership Appointments

The company has announced two strategic appointments to fill key positions effective May 1, 2026:

Chief Commercial Officer - Mr. Abhijit Zutshi

Mr. Abhijit Zutshi will assume the role of Chief Commercial Officer and become a member of the Executive Committee. He brings over two decades of experience at Biocon Limited, where he currently serves as Chief Commercial Officer with responsibility for Generics business Commercial operations.

Key highlights of his experience:

• Successful leadership across marketing, sales, business development and portfolio selection for small molecules and biologics
• Previously served as Commercial Head of Global Generics Formulations
• Instrumental in establishing commercial infrastructure in the U.S. for Biocon's formulation business
• Led the successful launch of Biocon's first generic formulation in the U.S. in 2017
• Former head of Biocon's North American operations
• Prior experience with Pfizer as a product specialist
• Educational background includes a bachelor's degree in Pharmaceutical Science with Pharmacology major, Diploma in Business Management, and Harvard Business School's Program for Leadership Development

Chief Human Resources Officer - Ms. Maninder Singh Puri

Ms. Maninder Singh Puri will take on the role of Chief Human Resources Officer and join the Executive Committee as Senior Management Personnel.

Professional background:

• Currently serves as Head of Human Resources for Generics Business and Biocon Academy
• Over 25 years of professional experience in leadership positions
• Former Global Chief Human Resources and Diversity Officer at Mastek Group
• Previous roles with Accenture, iGATE (now Cap Gemini), and Firstsource Solutions
• Recognized as "CHRO for the year 2022"
• Educational qualifications include Masters in English Literature and CHRO degree from Wharton Business School
• Passionate advocate for Diversity, Equity, Inclusion and Belonging (DEIB)

Regulatory Compliance

The management changes were disclosed in compliance with Regulation 30 read with Para A (7) of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that detailed information regarding these changes will be made available on its official website at www.syngeneintl.com .

These leadership transitions reflect the company's strategic approach to maintaining operational continuity while bringing in experienced professionals to drive future growth initiatives.